Just to clarify, as I said before, the mandate is that the BMC, the biologics manufacturing centre, will have a public-good mandate. It's not intended to compete with the private sector but to actually complement it, and complement it in such fashion that we'll be ready to manufacture and provide the capacity to manufacture in response to public health needs when the domestic market is unable to meet it. That's one thing.
Secondly, the key thing will be that the costs are recoverable. What that means is that while the government is giving us funds to build the facility, in terms of the production we will make sure that, as it is producing, the cost to produce will be recovered.